New York Life Investment Management LLC Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)

New York Life Investment Management LLC boosted its holdings in Repligen Co. (NASDAQ:RGEN) by 6.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,904 shares of the biotechnology company’s stock after buying an additional 375 shares during the period. New York Life Investment Management LLC’s holdings in Repligen were worth $1,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. abrdn plc grew its position in shares of Repligen by 1.4% during the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after purchasing an additional 71 shares in the last quarter. Signaturefd LLC grew its holdings in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Repligen by 14.8% during the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 87 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Repligen by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after buying an additional 100 shares in the last quarter. Finally, State of Michigan Retirement System boosted its position in shares of Repligen by 0.8% during the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after acquiring an additional 100 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of research reports. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. KeyCorp lifted their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Stock Down 0.2 %

Shares of NASDAQ RGEN opened at $167.72 on Wednesday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The firm’s 50-day moving average price is $179.84 and its 200-day moving average price is $174.62. The stock has a market capitalization of $9.37 billion, a price-to-earnings ratio of 670.91, a P/E/G ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. On average, equities research analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Buying and Selling

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 over the last three months. 1.20% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.